Rebif (human IFN-β-1a) / EMD Serono  >>  Phase 2
Welcome,         Profile    Billing    Logout  

26 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rebif (human IFN-β-1a) / EMD Serono
ACTRN12622000258752: INFINiTE-CV2 Phase IIa Trial: INterFeron type 1 Intra-Nasal gel Therapy for Early treatment of SARS-CoV2 (COVID-19)

Not yet recruiting
2
100
 
IntraVital, IntraVital Pty Ltd
COVID-19
 
 
NCT00303381: Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis

Completed
2
194
Europe, RoW
Interferon-beta-1a, 44 microgram, Rebif®, Placebo, Interferon-beta-1a, 66 microgram
EMD Serono, Merck Serono International SA
Ulcerative Colitis
01/03
01/03
NCT00304252: Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease

Terminated
2
192
Europe
Interferon beta-1a
EMD Serono
Crohn's Disease
 
09/03
NCT00050778: A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Checkmark AAN 2014: Multiple sclerosis (CAMMS223 & CARE MS I & CARE MS II)
Feb 2014 - Feb 2014: AAN 2014: Multiple sclerosis (CAMMS223 & CARE MS I & CARE MS II)
Checkmark
Oct 2013 - Oct 2013: 
Checkmark CAMMS223
More
Completed
2
334
US, Europe, RoW
Interferon beta-1a, Rebif®, Alemtuzumab 12 mg, Lemtrada, Alemtuzumab 24 mg
Genzyme, a Sanofi Company, Bayer
Multiple Sclerosis, Relapsing-Remitting
09/07
01/10
REAL, NCT01075763: A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease

Completed
2
42
Europe
Interferon beta-1a, Rebif®, Placebo
Merck KGaA, Darmstadt, Germany, Merck Serono S.P.A., Italy
Alzheimer's Disease
05/08
05/08
NCT00489489 / 2006-003134-14: Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Completed
2
118
US, Canada, Europe
Teriflunomide, HMR1726, Placebo (for Teriflunomide), Interferon-β, Avonex®, Rebif®, Betaseron®
Sanofi
Multiple Sclerosis
06/09
06/09
NCT00811395 / 2007-003997-24: Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Completed
2
182
US, Canada, Europe
Teriflunomide, HMR1726, Placebo (for teriflunomide), Interferon-β [IFN-β], Avonex®, Rebif®, Betaseron®, Glatiramer Acetate [GA], Copaxone®
Sanofi
Multiple Sclerosis
04/10
04/10
RECYCLINE, NCT01134627 / 2005-004289-18: Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]

Terminated
2
305
Europe
Minocycline, Placebo
Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
04/11
04/11
REPAIR, NCT01171209 / 2009-016824-29: REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients

Completed
2
10
Europe
Interferon-beta and human leukocyte Interferon-α, IFN-beta : Rebif, Betaferon, IFN-alfa: Multiferon®
Melinda Magyari, University of Copenhagen
Multiple Sclerosis
06/11
08/11
ONWARD, NCT00436826 / 2006-003366-33: A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease

Checkmark EAN 2016: ONWARD
Jun 2016 - Jun 2016: EAN 2016: ONWARD
Checkmark AAN 2016: ONWARD
Mar 2016 - Mar 2016: AAN 2016: ONWARD
Checkmark AAN 2013
More
Completed
2
172
Europe, US, RoW
Cladribine, Placebo, Interferon-beta (IFN-beta), Avonex®, Betaseron®, RNF
EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis
09/11
03/12
TERIVA, NCT01403376 / 2011-001160-21: Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide

Checkmark AAN 2013
Jan 2013 - Jan 2013: AAN 2013
Completed
2
128
Canada, Europe, RoW
teriflunomide, HMR1726, Interferon-β-1, Rebif®, Avonex®, Betaseron®, Betaferon®, Extavia®, Genfaxone®, Influenza vaccine
Sanofi
Multiple Sclerosis
01/12
01/12
NCT01404117: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability

Withdrawn
2
0
US
Laquinimod 0.6, Laquinimod 1.2, Glatiramer Acetate or interferon-beta+ Placebo
Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Multiple Sclerosis
12/13
01/14
CHOLINE, NCT01198132 / 2009-013695-46: A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly

Completed
2
129
Europe
Cholecalciferol (Vitamin D3), Vitamin D3, Placebo, Rebif, Interferon beta-1a
Merck KGaA, Darmstadt, Germany, Merck Serono S.A.S, France
Multiple Sclerosis
03/15
11/15
SOLAR, NCT01285401 / 2010-020328-23: Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Completed
2
260
Europe
VigantOL oil plus interferon beta-1a (Rebif), Placebo plus interferon beta-1a (Rebif), Interferon beta-1a (Rebif®) alone
Merck KGaA, Darmstadt, Germany
Relapsing-Remitting Multiple Sclerosis
04/15
05/15
2005-005751-18: A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies (NAbs) to IFNB-1a (Rebif)

 
2
100
Europe
Rebif 44, Rebif 22, Betaferon 500mcg, Interferon beta 1a, Betaferon 500mcg, Rebif 44, Rebif 22, Rebif 44, Rebif 22
UCL Biomedicine R&D Unit
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system of unknown aetiology. It is the commonest cause of disability in young adults. The prevalence in the UK is approximately 125/100,000 of the population with an annual incidence of 6/100,000. Approximately 80,000 individuals are affected with MS in the UK.
 
 
2008-005656-24: ENSAYO CLÍNICO SOBRE LA EVOLUCIÓN Y EL IMPACTO DEL TRATAMIENTO FARMACOLÓGICO EN LA PERDIDA AXONAL PROGRESIVA EN PACIENTES QUE CON ESCLEROSIS MÚLTIPLE QUE HAN PRESENTADO UN PRIMER EPISODIO DESMIELINIZANTE

Ongoing
2
20
Europe
REBIF 22 microgramos solución inyectable, REBIF 22 microgramos solución inyectable
Dra. Rosario Blasco
Primer episodio desmielinizante con criterios de esclerosis múltiple (EM) confirmada por laboratorio que no haya consistido en neuritis óptica y que no tengan criterios de mal pronóstico definidos como: 9 ó +lesiones y/o lesiones que capten Gd, afectación cerebelosa, EDSS>2 a las tres semanas del inicio del episodio.
 
 
2008-000256-26: An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferonβ-1a (IFNβ-1a, Rebif®) therapy in the induction of tolerance to IFNβ in MS patients with neutralising antibodies (NAbs) to subcutaneous IFNβ-1a (Rebif® or Avonex®)

 
2
15
Europe
Mitoxantrone, PL 04515/0127, Mitoxantrone, Rebif®, Mitoxantrone, Rebif®
Queen Mary, University of London
Multiple Sclerosis
 
02/14
EMR200136-549, NCT01514370: Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a

Completed
2
80
Europe
IFN beta 1a 44 mcg TIW, Interferon beta 1a, Curcumin, Rebif, BCM95, Placebo
Merck KGaA, Darmstadt, Germany, Merck Serono S.P.A., Italy
Multiple Sclerosis
03/16
03/16
INCREASE, NCT03387046: A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)

Terminated
2
7
Europe
D-aspartate, Placebo, IFN beta-1a, Methylprednisolone
Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
01/19
01/19
2020-003872-42: Antiviral and Immunomodulatory Interferon-Beta in high-risk COVID-19 patients Valutazione dell’attività antivirale e immunomodulatoria di Interferone-Beta in pazienti COVID-19 anziani

Ongoing
2
60
Europe
Interferon beta-1a, [IFNb], Solution for injection, REBIF - 22 MCG/0.5 ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - CARTUCCIA (VETRO) - 1.5 ML (12 MILIONI UI/ML) 4 CARTUCCE
Istituto di Farmacologia Traslazionale - CNR, Regione Lazio, Istituto Nazionale per le malattie infettive "Lazzaro Spallanzani", Merck Healthcare KGaA, Istituto Superiore di Sanità, Istituto di Farmacologia Traslazionale - CNR
SARS-CoV 2 infection characterized by a National Early Warning Score lower or equal to 2 and symptoms present for less than 7 days Infezione da virus SARS-CoV 2 con sintomatologia presente da meno di 7 giorni e punteggio minore o uguale a 2 nella National Early Warning Score (NEWS), Early SARS-CoV 2 infection characterized by mild COVID-19 symptoms Stato iniziale di infezione da virus SARS-CoV 2 con sintomi lievi di COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
NCT05298670: Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients

Recruiting
2
80
RoW
MetFORMIN 1000 Mg Oral Tablet, Cidophage ®1000 mg tablets, CID, Giza, Egypt) tablet and Rebiff ® 44mcg or Avonex®, Interferon beta-1a, Rebiff ® 44mcg or Avonex®
German University in Cairo
Multiple Sclerosis
02/23
03/23
TLV-0326-24, NCT06510426: Early Interferon-beta Treatment for West-Nile Virus Infection

Recruiting
2
100
RoW
Rebif 44 MCG Per 0.5 ML Prefilled Syringe, Saline
Tel-Aviv Sourasky Medical Center
West Nile Virus, West Nile Fever Encephalitis, West Nile Fever Myelitis, West Nile Fever With Other Complications
07/25
12/25
NCT04079088: Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Withdrawn
2
300
NA
Placebo, BIIB061, Interferon-beta1, Avonex, Plegridy, Betaferon/Betaseron, Extavia, or Rebif, Glatiramer acetate, Copaxone, Glatopa
Biogen
Relapsing Multiple Sclerosis
09/24
09/24
NPC-Nivo, NCT06019130: Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

Recruiting
2
57
Europe
Nivolumab, Opdivo, Cisplatin, Cisplatin Teva, 5-Fluorouracil, Fluorouracil-GRY, Gemcitabine, Gemcitabin-GRY, Radiotherapy, Interferon beta-1a, Rebif, MRI, PET, Patient-Reported Outcomes
German Society for Pediatric Oncology and Hematology GPOH gGmbH, Deutsche Krebshilfe e.V., Bonn (Germany)
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms, Nasopharynx Cancer
01/26
01/28
NCT02330393: Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

Not yet recruiting
1/2
20
US
Anti-PD-L1 Monoclonal Antibody MSB0010718C, MSB0010718C, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RT, Recombinant Interferon Beta, Betantrone, Betaseron, Feron, IFN-B, Rebif, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells, MCPyV TAg-specific polyclonal autologous CD8-positive T cells, Laboratory Biomarker Analysis
Fred Hutchinson Cancer Research Center, National Cancer Institute (NCI)
Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma
01/19
 
NCT05936229: Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Withdrawn
1/2
24
US
Interferon Beta-1A, 145258-61-3, Avonex, BG9418, Rebif, Recombinant interferon beta-1a, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Computed Tomography, CAT Scan, Computed Axial Tomography, Computerized axial tomography (procedure), Positron Emission Tomography, Pet Scan, Positron emission tomography (procedure), Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Lumbar Puncture, LP, spinal tap, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection, Biological Sample Collection, Biopsy, BIOPSY_TYPE, Bx
Fred Hutchinson Cancer Center, Faron Pharmaceuticals Ltd
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
10/27
10/27

Download Options